Dual Cathepsin L/JAK-IN-1

Dual Cathepsin L/JAK-IN-1 (Compound A8) is a dual inhibitor of Cathepsin L (CTSL) and JAK, with IC50 values of 0.68 μM, 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for CTSL, JAK1/2/3, and TYK2, respectively. Dual Cathepsin L/JAK-IN-1 effectively blocks the activation of the MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. Dual Cathepsin L/JAK-IN-1 can be used in research on acute lung injury (ALI) [1].

Product Specifications

CAS Number

[2450279-41-9]

UNSPSC

12352005

Target

Cathepsin; Interleukin Related; JAK; p38 MAPK; STAT

Related Pathways

Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Inflammation/Immunology

Purity

98.47

Solubility

DMSO : 7.14 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CN1C=C(C2=CC=CC=C21)C3=CC=NC(NC4=CC=CC(N)=C4)=N3.Cl

Molecular Formula

C19H18ClN5

Molecular Weight

351.83

References & Citations

[1]Shen C, et al. Design, Synthesis, and Biological Evaluation of 2-Arylaminopyrimidine Derivatives as Dual Cathepsin L and JAK Inhibitors for the Treatment of Acute Lung Injury. J Med Chem. 2025 Jan 9;68 (1) :361-386.